Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Classifica tra le azioni #31258
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Prezzo delle azioni
$0.4097
Capitalizzazione di mercato
$14.48M
Variazione (1 giorno)
-9.16%
Variazione (1 anno)
-67.22%
Paese
IL
Scambia NeuroSense Therapeutics Ltd. (NRSN)

Categoria

Storico del rendimento da dividendi per NeuroSense Therapeutics Ltd. (NRSN)
Il rendimento da dividendi (TTM) di NeuroSense Therapeutics Ltd. (simbolo azionario: NRSN) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per NeuroSense Therapeutics Ltd. (NRSN) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE